Giovanni Bartolucci

2 papers in the library · 7 citations · publishing 2023-2024

Papers

Sort Most recent Most cited

Heart Rate Variability as a Potential Predictor of Response to Intranasal Esketamine in Patients with Treatment-Resistant Depression: A Preliminary Report.

Journal of Clinical Medicine August 14, 2024 Lorenzo Moccia, Giovanni Bartolucci, Maria Pepe et al. 7 citations

Background: Esketamine has received approval as a nasal spray (ESK-NS) for treatment-resistant depression (TRD) and evidence from real-world investigations has confirmed the effectiveness of ESK-NS, albeit with interindividual differences in response. Heart rate variability (HRV), defined as the fluctuation in time interval between consecutive heartbeats, can be used to measure autonomic...

DOI: 10.3390/jcm13164767 Full text Esketamine Mood disorders Personalized medicine Mental-health +4

Reduction in Cognitive Symptoms Following Intranasal Esketamine Administration in Patients With Chronic Treatment-resistant Depression: A 12-Week Case Series.

Journal of Psychiatric Practice July 1, 2023 Maria Pepe, Giovanni Bartolucci, Ilaria Marcelli et al.

Background: Cognitive symptoms are a core feature of depressive disorders, interfere with full functional recovery and are prominent in patients with treatment-resistant depression (TRD), particularly in severe chronic cases. Intranasal (IN) esketamine was recently approved for the treatment of TRD; however, its effects on cognitive symptoms are unclear. In this article, we describe cognitive...

DOI: 10.1097/pra.0000000000000723 Ketamine Depression Humans Antidepressive agents +3